期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

表皮生长因子受体酪氨酸激酶抑制剂在肿瘤治疗中的应用 被引量：14

Application of epidermal growth factor receptor tyrosine kinase inhibitors in cancer therapy
下载PDF
导出
摘要 表皮生长因子受体 (EGFR)酪氨酸激酶 ,是细胞外信号传递到细胞内的重要枢纽 ,它在信号传导、细胞增殖、分化以及各种调节机制中发挥重要作用 ,在多种癌细胞中过度表达。许多研究表明 ,抑制EGFR酪氨酸激酶活性 ,可抑制肿瘤生长。目前 ,已有几种EGFR酪氨酸激酶抑制剂进入了临床试验。本文对几种EGFR酪氨酸激酶小分子抑制剂在肿瘤治疗中的研究进展做一综述。 Epidermal growth factor receptor (EGFR) tyrosine kinase is over-expressed in numerous human tumors, which plays pivotal roles in cellular signal transduction, and it is involved in a variety of tumor cellular behaviors such as proliferation, metastasis, angiogenesis and so on. Many investigations have indicated that tumor growth can be suppressed by inhibiting EGFR tyrosine kinase activity. Currently, several EGFR tyrosine kinase inhibitors are in clinical trial stage.
作者 李哲 袁守军
机构地区 军事医学科学院放射医学研究所药理室
出处 《中国临床药理学与治疗学》 CAS CSCD 2004年第4期361-364,共4页 Chinese Journal of Clinical Pharmacology and Therapeutics
关键词 表皮生长因子受体 酪氨酸激酶抑制剂 肿 瘤治疗 临床试验 phacology epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors cancer therapy clinical trial
分类号 R966 [医药卫生—药理学] R979.1 [医药卫生—药品]
  • 相关文献

参考文献22

  • 1[1]Kathryn SK, Brian JD. Protein tyrosine kinases and cancer[ J].Biochimica Biophysica Acta, 1997; 1333(3) :217 - 48
  • 2[2]Fortunato C, Giampaolo T. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor[J]. Clin Cancer Res, 2001 ;7(10) :2958 - 70
  • 3[3]Bos M, Mendelsohn J, Kim YM, Albanell J, Fry DW, Basellga J, et al. PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor trceptor activation and inhibits growth of cancer cells in a receptor number- dependent manner[J]. Clin Cancer Res, 1997;3(11) :2099 - 106
  • 4[4]Woodburn JR, Barker AJ. 4-Anilinoquii-nazolines-a potential new therapy for major human solid tumors overexpressing the EGF receptor[J]. Br J Cancer, 1996;74(1) :18 - 24
  • 5[5]Di GE, Barbarino M, Bruzzese F, De Lorenzo S, Caraglia M,Abbruzzese A, et al. Critical role of both p27KIP1 and p21CIP1/WAF1 in the antiprolfferative effect of ZD1839 (‘ Iressa' ), an epidermal growth factor receptor tyrsine kinase inhibitor, in head and neck squamous carcinoma cells [ J]. J Cell Physiol, 2003;195(1):139-50
  • 6[6]Ciardiello F, Caputo R, Bianco R, Damianco V, Pomatico G,De Placido S, et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa),an epidermal growth factor receptor-sensitive tyrosine kinase inhibitor[J]. Clin Cancer Res,2000;6(5) :2053 - 63
  • 7[7]Solomon B, Hagekyriakou J, Trivett MK, Stacker SA,McArthur GA, Cullinane C. EGFR blockade with ZD1839(" Iressa") potentiates the antitumor effects of single and multiple fractions of ionzing radiation in human A431 squamous cell carcinoma, Epidermal growth factor receptor[J]. Int J Radiat Oncol Biol Phys, 2003; 55 (3): 713 - 23
  • 8[8]Baselga J, Rischin D, Ranson M, Calvert H, Raymond E,Kieback DG, et al. Phase Ⅰ safety, pharmacokinetic, and pharmacodlynamic trial of ZD1839, a selective oral epidemal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types[J]. J Clin Oncol,2002;20(21 ):4292 - 302
  • 9[9]Miller VA, Johnson D, Heelan RT, Pizzo BA, Perez WJ, Bass A, et al. A pilot trial demonstrates the safety of ZD1839 (Iressa), an oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in combination with carboplatin (C) and paclitaxcl (P) in previously untreated advanced nor-small lurg cancer (NSLC)[J]. Proo c Soc Clin Oncol,2001 ;21:326
  • 10[10]Perter T, Guido B, Elisaleth B, Giorgio C, Pascal F, Paul M,et al. Tyrosine Kinase Inhibitors:From Rational Design to Clinical Trials[J]. Med Res Rev,2001 ;21(6) :499 - 512

同被引文献184

引证文献14

二级引证文献98

中国临床药理学与治疗学
2004年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部